摘要 |
This disclosure describes, in one aspect, immunogens effective for treating and/or diagnosing tauopathy, and immunotherapeutic compositions and methods involving those immunogens. Generally, the immunogen includes an antigen presentation component and a microtubule-associated tau protein (MAPT) component linked to at least a portion of the antigen presentation component. This disclosure describes, in another aspect, a transgenic mouse. Generally, the transgenic mouse possesses brain cells that have a polynucleotide that encodes human microtubule-associated protein tau (MAPT). The polynucleotide further exhibits a deletion of at least a portion of endogenous mouse MAPT. The transgenic mouse also includes a forebrain neuron-specific deletion of a polynucleotide that encodes Myeloid Differentiation Primary Response Gene 88 (MyD88). In a further aspect, this disclosure describes a method of producing the transgenic mouse. |
申请人 |
STC. UNM;BHASKAR, Kiran;MAPHIS, Nicole;PEABODY, David, S.;CHACKERIAN, Bryce;PEABODY, Julianne;CROSSEY, Erin |
发明人 |
BHASKAR, Kiran;MAPHIS, Nicole;PEABODY, David, S.;CHACKERIAN, Bryce;PEABODY, Julianne;CROSSEY, Erin |